<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773315</url>
  </required_header>
  <id_info>
    <org_study_id>02-2018-029</org_study_id>
    <nct_id>NCT03773315</nct_id>
  </id_info>
  <brief_title>Ulmus Macrocarpa Hance Extract and Lipid Profile</brief_title>
  <official_title>Effect of Ulmus Macrocarpa Hance Extract on Lipid Profile in Adults With Dyslipidemia: a RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sang Yeoup Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate
      the effects of the Ulmus Macrocarpa Hance extract on lipid profile in adults with
      dyslipidemia for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous another our study have indicated that Ulmus Macrocarpa Hance extract (UMH) may have
      the ability to decrease blood cholesterol. Therefore, the investigators conduct a randomized,
      double-blind, placebo-controlled study to investigate the effects of the UMH on lipid profile
      in adults with dyslipidemia; the safety of the compound are also evaluate. The Investigators
      examine total cholesterol, HDL-cholesterol, triglyceridemia, LDL-cholesterol, and other
      biochemical parameters at baseline, as well as after 6 and 12 weeks of intervention. Eighty
      adults were administered either 500 mg of UMH or a placebo each day for 12 weeks;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>LDL cholesterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL cholesterol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>UMH group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes UMH extract for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group takes placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>UMH extract</intervention_name>
    <description>Schisandra chinensis extract 500 mg/day for 12 weeks</description>
    <arm_group_label>UMH group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starch placebo 500 mg/day for 12 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL cholesterol ranging from 130 to 190 mg/dL

        Exclusion Criteria:

          -  Abnormal liver or renal function (i.e., serum aminotransferase activity &gt; 80 IU/L and
             serum creatinine concentrations &gt; 1.2 mg/dL)

          -  Diabetes (diagnosed clinically or fasting glucose level &gt; 126 mg/dL)

          -  History of ischemic heart disease or cerebrovascular disease

          -  Uncontrolled hypertension

          -  History of serious cardiac disease such as angina or myocardial infarction

          -  History of gastrectomy

          -  History of medication for psychiatric disease

          -  Administration of oriental medicine including herbs within the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Integrated Research Institute for Natural Ingredients and Functional Foods</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

